Actively Recruiting
Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy
Led by The Cooper Health System · Updated on 2026-04-15
100
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
Sponsors
T
The Cooper Health System
Lead Sponsor
T
The Cooper Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if using an incentive spirometer can reduce lung problems in people with advanced lung cancer who are receiving chemotherapy and radiation therapy. The main questions the study aims to answer are: Does using an incentive spirometer lower the chances of developing lung inflammation (pneumonitis)? Does it improve overall survival and quality of life? Participants will: Use an incentive spirometer, a device that helps with deep breathing, 10 times every hour while awake. Continue using the spirometer daily during treatment and for up to three months after treatment. Complete quality of life assessments at the start of the study and at 3, 6, and 12 months. Researchers will compare the results to see if the incentive spirometer helps reduce lung problems and improves participants\' well-being during and after their cancer treatment.
CONDITIONS
Official Title
Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of advanced non-small-cell lung cancer
- Performance status (ECOG 0-1)
- Eligible for concurrent chemotherapy and radiation
- 18 years or older
You will not qualify if you...
- Previous lung or thoracic surgery
- Enrollment in another pulmonary intervention trial
- Home oxygen usage prior to enrolment
- Radiological evidence of pleural effusion, pneumothorax, bullous emphysema, or pneumonitis on staging imaging
- Presence of active respiratory tract infection
- Uncontrolled nausea and vomiting
- Prior exposure to drugs such as amiodarone, bleomycin, or immunotherapy
- Inability or unwillingness to give written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
MD Anderson Cancer Center at Cooper
Camden, New Jersey, United States, 08103
Actively Recruiting
Research Team
V
Veli Bakalov, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here